| pubmed-article:7843855 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7843855 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:7843855 | lifeskim:mentions | umls-concept:C0037993 | lld:lifeskim |
| pubmed-article:7843855 | lifeskim:mentions | umls-concept:C0002771 | lld:lifeskim |
| pubmed-article:7843855 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:7843855 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:7843855 | lifeskim:mentions | umls-concept:C0031959 | lld:lifeskim |
| pubmed-article:7843855 | lifeskim:mentions | umls-concept:C0293818 | lld:lifeskim |
| pubmed-article:7843855 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:7843855 | pubmed:dateCreated | 1995-3-3 | lld:pubmed |
| pubmed-article:7843855 | pubmed:abstractText | The immunoregulatory effects of fentanyl and a fentanyl-related compound, OHM3295, were studied in mice. Male CD1 mice treated with a range of fentanyl doses (0.1-1.0 mg/kg, subcutaneously) showed suppression of splenic natural killer (NK) activity following 0.25-0.50 mg/kg fentanyl dose but not higher (0.75-1.0 mg/kg) or lower (0.1 mg/kg) doses. Fentanyl (0.01-32.0 mg/kg) also induced dose-related analgesia as measured by an increase in tail flick latency; these analgesic effects were antagonized by naltrexone (1.0-10.0 mg/kg). Pretreatment with naltrexone (1.0-3.2 mg/kg) resulted in significant suppression of splenic NK activity following fentanyl (10.0-32.0 mg/kg) administration. In comparison to fentanyl, OHM3295 (3.2-25.0 mg/kg) augmented splenic NK activity in a naltrexone-reversible manner. Similar to fentanyl, OHM3295 (1.0-32.0 mg/kg) also induced a naltrexone-sensitive, dose-related analgesia as measured by an increase in tail flick latency. These results with OHM3295 demonstrate a novel profile of effects which includes naltrexone-sensitive analgesic effects in the absence of immunosuppressive effects. In addition, this is the first reported case in which a compound with opioid analgesic effects has been shown to potentiate natural killer cytolytic activity following in vivo administration. | lld:pubmed |
| pubmed-article:7843855 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7843855 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7843855 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7843855 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7843855 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7843855 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7843855 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7843855 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7843855 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7843855 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7843855 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:7843855 | pubmed:issn | 0192-0561 | lld:pubmed |
| pubmed-article:7843855 | pubmed:author | pubmed-author:BakerM LML | lld:pubmed |
| pubmed-article:7843855 | pubmed:author | pubmed-author:FranceC PCP | lld:pubmed |
| pubmed-article:7843855 | pubmed:author | pubmed-author:HolmesCC | lld:pubmed |
| pubmed-article:7843855 | pubmed:author | pubmed-author:BagleyJ RJR | lld:pubmed |
| pubmed-article:7843855 | pubmed:author | pubmed-author:CarrD JDJ | lld:pubmed |
| pubmed-article:7843855 | pubmed:author | pubmed-author:BrockunierL... | lld:pubmed |
| pubmed-article:7843855 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7843855 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:7843855 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7843855 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7843855 | pubmed:pagination | 835-44 | lld:pubmed |
| pubmed-article:7843855 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:7843855 | pubmed:meshHeading | pubmed-meshheading:7843855-... | lld:pubmed |
| pubmed-article:7843855 | pubmed:meshHeading | pubmed-meshheading:7843855-... | lld:pubmed |
| pubmed-article:7843855 | pubmed:meshHeading | pubmed-meshheading:7843855-... | lld:pubmed |
| pubmed-article:7843855 | pubmed:meshHeading | pubmed-meshheading:7843855-... | lld:pubmed |
| pubmed-article:7843855 | pubmed:meshHeading | pubmed-meshheading:7843855-... | lld:pubmed |
| pubmed-article:7843855 | pubmed:meshHeading | pubmed-meshheading:7843855-... | lld:pubmed |
| pubmed-article:7843855 | pubmed:meshHeading | pubmed-meshheading:7843855-... | lld:pubmed |
| pubmed-article:7843855 | pubmed:meshHeading | pubmed-meshheading:7843855-... | lld:pubmed |
| pubmed-article:7843855 | pubmed:meshHeading | pubmed-meshheading:7843855-... | lld:pubmed |
| pubmed-article:7843855 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:7843855 | pubmed:articleTitle | OHM3295: a fentanyl-related 4-heteroanilido piperidine with analgesic effects but not suppressive effects on splenic NK activity in mice. | lld:pubmed |
| pubmed-article:7843855 | pubmed:affiliation | Department of Microbiology, LSU Neuroscience Center, Louisiana State University Medical Center, New Orleans 70112-1393. | lld:pubmed |
| pubmed-article:7843855 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7843855 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:7843855 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
